DemineralisationNCT01344473
A Trial of Tooth Mousse to Remineralise Post-orthodontic Treatment White Spot Lesions
A study testing Tooth Mousse creme (Casein Phosphopeptide)(RECALDENT) in people with Demineralisation and White Spot Lesions, run by University of Dundee at 2 sites in United Kingdom.
Trial summary
Fixed dental braces are associated with the risk of developing White Spot Lesions (WSLs), which appear as white chalky marks on the teeth. They develop as a result of the acid produced by bacteria in dental plaque dissolving the outer surface of the tooth, known as demineralisation. Read more about this study
- Who is it for?
- Ages 10 years and older
- Conditions the study is for
- Demineralisation, White Spot Lesions, Orthodontic Treatment
- What is being tested?
- Tooth Mousse creme (Casein Phosphopeptide)(RECALDENT)
- Type of treatment
- Pill or oral medicine, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 90 participants
- Where
- 2 sitesUnited Kingdom
- Study dates
- Mar 2011to Nov 2013
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 10 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Single or both arch fixed orthodontic appliance treatment completed
- Being provided with a vacuum formed retainer(s)
- Participant, or parent or guardian of participant if less than 12 years, gives written informed consent
Who cannot join
- Tooth Mousse used during orthodontic treatment
- Having a bonded retainer
- Not receiving a vacuum formed retainer
- Suffers from psychiatric or behavioural problems which may affect ability to follow study instructions
- Resting salivary flow rate less than 0.2ml/minute
- Stimulated salivary flow rate less than 1.0ml/minute
Show all 9Show fewer
- Allergic to milk proteins or benzoate derivatives
- Unable to read and understand PIL, ICF and questionnaires
- Taking medication which may affect salivary flow
Trial locations and contacts
2 sites in 1 country.
United Kingdom2 sites
Dundee Dental Hospital
Dundee, DD1 4HN
Perth Royal Infirmary
Perth, PH1 1NX
About this study
Official title: A Randomised Controlled Trial of Tooth Mousse to Remineralise Post-orthodontic Treatment White Spot Lesions
Fixed dental braces are associated with the risk of developing White Spot Lesions (WSLs), which appear as white chalky marks on the teeth. They develop as a result of the acid produced by bacteria in dental plaque dissolving the outer surface of the tooth, known as demineralisation. Recently, amorphous calcium phosphate (ACP) stabilised by casein phosphopeptide (CPP) has become available, and it is reported to help rebuild the surface of teeth which have WSLs. CPP-ACP is available incorporated into a crème known as Tooth Mousse (TM). While there appears to be sufficient evidence regarding the use of CPP-ACP in promoting general remineralisation, for the first time this study aims to examine the use of CPP-ACP to treat WSLs in post-orthodontic participants.
Read the detailed description
The study will be run in the Orthodontic departments of Dundee Dental School and Perth Royal Infirmary, both in NHS Tayside. The investigators will recruit a total of 80 participants to the study. Clinicians within the orthodontic departments will determine when a patient could be a potential participant of the study, and one visit prior to debonding of their brace, the treating clinician will discuss the study with the potential participant. If they are interested in finding out more, the clinician will issue the potential participant with the appropriate PIL. There will be a PIL for potential participants over sixteen years old, and separate PILs for those aged twelve to sixteen years old, under twelve years old, and for parents/guardians of potential participants under sixteen years old.. The clinician will then inform the PI/SI that a PIL and supporting documentation has been issued. There will be a potential participant referral form, which can be completed to aid the transfer of information to the PI/SI. Potential participants under twelve years old will be advised that a parent or guardian must attend with them for the debond appointment, when written informed consent (IC) will be sought from the parents/guardians by the Investigators of the study.
Once IC has been obtained, resting and stimulated salivary flow rate will be measured by the Investigators or delegated member of the research team using a Saliva-Check Buffer kit (GC Corp, Leuven, Belgium). The kit will allow observation of the quantity and viscosity of resting saliva produced in one minute, and the pH of the sample will also be tested and recorded. Participants will then chew a piece of paraffin wax for a two-minute period to produce a stimulated salivary sample. The liquid component of the sample will be measured to allow a flow rate in ml/minute to be calculated, and the pH again tested and recorded. The buffering capacity of the stimulated saliva will also be determined by challenging the saliva with varying amounts of lactic acid. As a lack of saliva would bias the results for the study due to increased caries risk, and as saliva is essential for the hydrolysis of the CPP-ACP from the TM, if the resting salivary flow rate is below 0.2ml/min, or the stimulated rate below 1.0ml/min, then the subject will be excluded from the study. Participants will then be randomly allocated to the control or the experimental group.
Each subject included in the study will have their WSLs assessed and categorised clinically using the International Caries Detection and Assessment System, (ICDASii) (International Caries Detection and Assessment System Coordinating Committee, 2009a), by ICDASii calibrated examiners. Examiner reliability will be determined by scoring extracted teeth and teeth validated by histology. Reproducibility will be measured using Kappa scores. All lesions on the buccal surfaces of teeth will be included in the study. Intra-oral digital photographs will also be taken of each participant in a reproducible manner, and the photographs analysed by two different blinded ICDASii calibrated examiners, who will be recruited to the study simply to score the clinical photographs. A colour standard (CasMaTCH; Bear medic, Tokyo) will be used to allow colour matching of the images.
The experimental group will receive TM crème to use daily. The oral and written instructions regarding crème application will be provided, indicating that the crème should be applied to all surfaces of the teeth, agitated (swished) for one minute and then retainers placed for night-time wear as per crème application protocol.
Subjects in the control group will not use any crème in their retainers, but will simply be asked to place their retainer for night-time wear.
At commencement of the study it will be recorded how long participants fixed appliances had been in situ, and all participants and clinicians will receive a questionnaire to determine their fluoride use, oral hygiene regime, diet and preventive interventions e.g. visits to hygienist, topical fluoride application, during their fixed appliance treatment. The participants dental records will be reviewed and any record of pre-existing developmental defects of enamel or WSLs will be documented. Participants will be asked to score their own perception of the appearance of their teeth, considering the presence of their WSLs, using a validated Visual Analogue Scale (VAS).
Participants will be reviewed at 6 weeks and at 12 weeks. At both visits WSLs will be reassessed and categorised by a calibrated examiner (PI/SI) using ICDASii. Digital photographs will be retaken for analysis by other blinded, calibrated examiners and the where appropriate, the participants will be asked to bring their tube of unused crème to be weighed to help determine compliance to the study protocol. A decision has been made not to issue subject diaries to determine compliance as evidence in the Orthodontic literature hasn't found self-reporting of this type, in this area to be reliable. Participants will be asked to score the appearance of their teeth using the VAS again and subjects in the experimental group will complete a questionnaire on acceptability, taste and convenience of using the crème.
A transition matrix incorporating ICDASii severity and activity scores will be used to assess the stability, regression or progression of WSLs between baseline and follow-up examinations.
- Conditions
- Demineralisation, White Spot Lesions, Orthodontic Treatment
- Being tested
- Tooth Mousse creme (Casein Phosphopeptide)(RECALDENT)
- Keywords
- Remineralisation, White Spot Lesions, Orthodontic treatment, Tooth Mousse creme, Casein Phosphopeptide
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Tooth Mousse creme (Casein Phosphopeptide)(RECALDENT)Device
Also called RECALDENT
TM is a water based creme containing RECALDENT. RECALDENT consists of CPP-AP: Casein Phosphopeptide - Amorphous Calcium Phosphate.
| Study group | Role | What they receive |
|---|---|---|
| Casein phosphopeptide in the form of TM | Experimental | Experimental group will be given TM to use daily for 12 weeks Receives: Device: Tooth Mousse creme (Casein Phosphopeptide)(RECALDENT) |
| No intervention | No intervention | Standard oral care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Effectiveness of TM to promote remineralisation of WSLs
To determine the effectiveness of TM to promote remineralisation of WSLs in post orthodontic treatment study patients. Patients will be reviewed at 6 weeks and 12 weeks. At both visits WSLs will be reassessed and categorised by a calibrated examiner using the International Caries Detection and Assessment System (ICDASii) for scoring lesions. Examiner reliability will be determined by scoring extracted teeth and teeth validated by histology. Intra-oral photographs will also be taken of each participant and the photographs analysed by two different blinded ICDASii calibrated examiners.
Measured: 12 weeks
Participants' perception of the appearance of their WSLs
To determine the change in study participants' perceptions of the appearance of their WSLs after using TM or no TM in their orthodontic retainers. Patients will be asked to score their own perception of the appearance of their teeth, considering the presence of their WSLs, using a Visual Analogue Score (VAS).
Measured: 12 weeks
Secondary outcomes (3)
Information on oral hygiene regimes and fluoride use during the period of fixed appliance treatment.
This outcome aims to obtain information on oral hygiene regimes and fluoride use during fixed appliance treatment of study participants who exhibit WSLs at the end of fixed appliance treatment. At the time of recruitment, it will be recorded how long participants' fixed appliances had been in situ and all participants and clinicians will receive a questionnaire to determine their fluoride use, oral hygiene regime, diet and preventive interventions e.g. visits to hygienist etc during their fixed appliance treatment.
Measured: Week 0
Assess severity and location of WSLs in orthodontic treatment
At the time of recruitment, and immediatly after removal of their fixed appliance, the participants will have the severity and location of their WSLs assessed and categorised clinically using the ICDASii calibrated examiners. All lesions on the buccal surfaces of the teeth will be included in the study. Intra-oral digital photographs will also be taken of each participant and the photographs analysed by two different blinded ICDASii calibrated examiners.
Measured: Week 0
Compare ICDASii scores in different assessment techniques
To compare the ICDASii scores of WSLs determined clinically with ICDASii scores of the same WSLs determined using digital photography 6 weeks and 12 weeks after debond of their appliance.
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Apr 2011 (estimated)
- Study startMar 2011
- Primary completionAug 2013
- Study completionNov 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for DemineralisationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 90 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Dundee
- Sponsor type
- University, hospital or other
- Collaborators
- NHS Tayside
- Responsible party
- Principal investigator, Fiona Hogarth, University of Dundee
- Investigators
- David Bearn, M(Orth)RCS PhD BDS, Principal investigator, University of DundeeLouise Greene, MFDS BDS, Principal investigator, NHS Tayside
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01344473
- Sponsor's protocol ID
- 2010DE11
- Status last verified
- Jan 2014
- First submitted
- 7 Apr 2011
- Last updated
- 13 Jan 2014
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Manton DJ, Shen P, Cai F, Cochrane NJ, Reynolds C, Messer LB, Reynolds EC. Remineralisation of WSLs in situ by TM. (Abstract) IADR 84th General Session, Brisbane 2006.
Morgan MV, Bailey D, Adams G, Tsao C, Hyslop A, Escobar K, Manton DJ, Reynolds E. A clinical study measuring white spot lesion progression and regression. (Abstract) J Dent Res 2008: 87 (special issue B): 11-4
Study at a glance
From the registry record, last updated by the sponsor on 13 Jan 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomised Controlled Trial of Tooth Mousse to Remineralise Post-orthodontic Treatment White Spot Lesions
- ClinicalTrials.gov ID
- NCT01344473
- Acronym / sponsor ID
- 2010DE11
- Conditions
- Demineralisation, White Spot Lesions, Orthodontic Treatment
- Keywords
- Remineralisation, White Spot Lesions, Orthodontic treatment, Tooth Mousse creme, Casein Phosphopeptide
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 90 participants (actual)
- Lead sponsor
- University of DundeeUniversity, hospital or other
- Collaborators
- NHS Tayside
- Study start
- Mar 2011
- Primary completion
- Aug 2013 (actual)
- Study completion
- Nov 2013 (actual)
- First posted
- 29 Apr 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Fixed dental braces are associated with the risk of developing White Spot Lesions (WSLs), which appear as white chalky marks on the teeth. They develop as a result of the acid produced by bacteria in dental plaque dissolving the outer surface of the tooth, known as demineralisation. Recently, amorphous calcium phosphate (ACP) stabilised by casein phosphopeptide (CPP) has become available, and it is reported to help rebuild the surface of teeth which have WSLs. CPP-ACP is available incorporated into a crème known as Tooth Mousse (TM). While there appears to be sufficient evidence regarding the use of CPP-ACP in promoting general remineralisation, for the first time this study aims to examine the use of CPP-ACP to treat WSLs in post-orthodontic participants.
Detailed description
The study will be run in the Orthodontic departments of Dundee Dental School and Perth Royal Infirmary, both in NHS Tayside. The investigators will recruit a total of 80 participants to the study. Clinicians within the orthodontic departments will determine when a patient could be a potential participant of the study, and one visit prior to debonding of their brace, the treating clinician will discuss the study with the potential participant. If they are interested in finding out more, the clinician will issue the potential participant with the appropriate PIL. There will be a PIL for potential participants over sixteen years old, and separate PILs for those aged twelve to sixteen years old, under twelve years old, and for parents/guardians of potential participants under sixteen years old.. The clinician will then inform the PI/SI that a PIL and supporting documentation has been issued. There will be a potential participant referral form, which can be completed to aid the transfer of information to the PI/SI. Potential participants under twelve years old will be advised that a parent or guardian must attend with them for the debond appointment, when written informed consent (IC) will be sought from the parents/guardians by the Investigators of the study.
Once IC has been obtained, resting and stimulated salivary flow rate will be measured by the Investigators or delegated member of the research team using a Saliva-Check Buffer kit (GC Corp, Leuven, Belgium). The kit will allow observation of the quantity and viscosity of resting saliva produced in one minute, and the pH of the sample will also be tested and recorded. Participants will then chew a piece of paraffin wax for a two-minute period to produce a stimulated salivary sample. The liquid component of the sample will be measured to allow a flow rate in ml/minute to be calculated, and the pH again tested and recorded. The buffering capacity of the stimulated saliva will also be determined by challenging the saliva with varying amounts of lactic acid. As a lack of saliva would bias the results for the study due to increased caries risk, and as saliva is essential for the hydrolysis of the CPP-ACP from the TM, if the resting salivary flow rate is below 0.2ml/min, or the stimulated rate below 1.0ml/min, then the subject will be excluded from the study. Participants will then be randomly allocated to the control or the experimental group.
Each subject included in the study will have their WSLs assessed and categorised clinically using the International Caries Detection and Assessment System, (ICDASii) (International Caries Detection and Assessment System Coordinating Committee, 2009a), by ICDASii calibrated examiners. Examiner reliability will be determined by scoring extracted teeth and teeth validated by histology. Reproducibility will be measured using Kappa scores. All lesions on the buccal surfaces of teeth will be included in the study. Intra-oral digital photographs will also be taken of each participant in a reproducible manner, and the photographs analysed by two different blinded ICDASii calibrated examiners, who will be recruited to the study simply to score the clinical photographs. A colour standard (CasMaTCH; Bear medic, Tokyo) will be used to allow colour matching of the images.
The experimental group will receive TM crème to use daily. The oral and written instructions regarding crème application will be provided, indicating that the crème should be applied to all surfaces of the teeth, agitated (swished) for one minute and then retainers placed for night-time wear as per crème application protocol.
Subjects in the control group will not use any crème in their retainers, but will simply be asked to place their retainer for night-time wear.
At commencement of the study it will be recorded how long participants fixed appliances had been in situ, and all participants and clinicians will receive a questionnaire to determine their fluoride use, oral hygiene regime, diet and preventive interventions e.g. visits to hygienist, topical fluoride application, during their fixed appliance treatment. The participants dental records will be reviewed and any record of pre-existing developmental defects of enamel or WSLs will be documented. Participants will be asked to score their own perception of the appearance of their teeth, considering the presence of their WSLs, using a validated Visual Analogue Scale (VAS).
Participants will be reviewed at 6 weeks and at 12 weeks. At both visits WSLs will be reassessed and categorised by a calibrated examiner (PI/SI) using ICDASii. Digital photographs will be retaken for analysis by other blinded, calibrated examiners and the where appropriate, the participants will be asked to bring their tube of unused crème to be weighed to help determine compliance to the study protocol. A decision has been made not to issue subject diaries to determine compliance as evidence in the Orthodontic literature hasn't found self-reporting of this type, in this area to be reliable. Participants will be asked to score the appearance of their teeth using the VAS again and subjects in the experimental group will complete a questionnaire on acceptability, taste and convenience of using the crème.
A transition matrix incorporating ICDASii severity and activity scores will be used to assess the stability, regression or progression of WSLs between baseline and follow-up examinations.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Casein phosphopeptide in the form of TM | Experimental | Device: Tooth Mousse creme (Casein Phosphopeptide)(RECALDENT)Experimental group will be given TM to use daily for 12 weeks |
| No intervention | No intervention | –Standard oral care |
Who may qualify
- Ages
- 10 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (3 listed)
- Single or both arch fixed orthodontic appliance treatment completed
- Being provided with a vacuum formed retainer(s)
- Participant, or parent or guardian of participant if less than 12 years, gives written informed consent
Key exclusion criteria (9 listed)
- Tooth Mousse used during orthodontic treatment
- Having a bonded retainer
- Not receiving a vacuum formed retainer
- Suffers from psychiatric or behavioural problems which may affect ability to follow study instructions
- Resting salivary flow rate less than 0.2ml/minute
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tooth Mousse creme (Casein Phosphopeptide)(RECALDENT)Also: RECALDENTTM is a water based creme containing RECALDENT. RECALDENT consists of CPP-AP: Casein Phosphopeptide - Amorphous Calcium Phosphate. | Device | Casein phosphopeptide in the form of TM |
Primary outcome
Effectiveness of TM to promote remineralisation of WSLs
Time frame: 12 weeks
To determine the effectiveness of TM to promote remineralisation of WSLs in post orthodontic treatment study patients. Patients will be reviewed at 6 weeks and 12 weeks. At both visits WSLs will be reassessed and categorised by a calibrated examiner using the International Caries Detection and Assessment System (ICDASii) for scoring lesions. Examiner reliability will be determined by scoring extracted teeth and teeth validated by histology. Intra-oral photographs will also be taken of each participant and the photographs analysed by two different blinded ICDASii calibrated examiners.
Participants' perception of the appearance of their WSLs
Time frame: 12 weeks
To determine the change in study participants' perceptions of the appearance of their WSLs after using TM or no TM in their orthodontic retainers. Patients will be asked to score their own perception of the appearance of their teeth, considering the presence of their WSLs, using a Visual Analogue Score (VAS).
3 secondary outcomes
Information on oral hygiene regimes and fluoride use during the period of fixed appliance treatment.
Time frame: Week 0
Assess severity and location of WSLs in orthodontic treatment
Time frame: Week 0
Compare ICDASii scores in different assessment techniques
Time frame: 12 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jan 2014.
- BackgroundManton DJ, Shen P, Cai F, Cochrane NJ, Reynolds C, Messer LB, Reynolds EC. Remineralisation of WSLs in situ by TM. (Abstract) IADR 84th General Session, Brisbane 2006.
- BackgroundMorgan MV, Bailey D, Adams G, Tsao C, Hyslop A, Escobar K, Manton DJ, Reynolds E. A clinical study measuring white spot lesion progression and regression. (Abstract) J Dent Res 2008: 87 (special issue B): 11-4
Related trials for Demineralisation
Active, not recruiting
Clinical Evaluation of a New Dual-cure Universal Adhesive
Class I Dental Restorations, Class II Dental Restorations
Not yet recruiting
Safety of Intraosseous Anaesthesia in Children With Haemophilia
Haemophilia A, Haemophilia B
Not yet recruiting
Clinical and Radiographic Evaluation of Silver Diamine Fluoride Versus Light-Cured Silver Diamine Fluoride in Carious Primary Molars
Dental Caries
Not yet recruiting
Clinical Performance of CAD/CAM Hard Hybrid Ceramic Inlays Versus Resin Composite Inlays in Vital Molars With Extensive Occluso-Proximal Cavities
Dental Caries, Cavity, Dental
Not yet recruiting
Effect of Xylitol- Versus Erythritol-Sweetened Mints on Plaque ATP-Bioluminescence Readings
Dental Caries, Dental Plaque
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
David Bearn, M(Orth)RCS PhD BDS principal investigator
University of Dundee
Louise Greene, MFDS BDS principal investigator
NHS Tayside
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Tooth Mousse creme (Casein Phosphopeptide)(RECALDENT) in people with Demineralisation and White Spot Lesions, run by University of Dundee at 2 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Jan 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Effectiveness of TM to promote remineralisation of WSLs (time frame: 12 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01344473, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jan 2014.